About Acorda Therapeutics (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ACOR
- CUSIP: 00484M10
- Web: www.acorda.com
Capitalization:- Market Cap: $1.27 billion
- Outstanding Shares: 46,640,000
Average Prices:- 50 Day Moving Avg: $24.20
- 200 Day Moving Avg: $19.91
- 52 Week Range: $13.60 - $33.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 38.86
- P/E Growth: 0.51
Sales & Book Value:- Annual Revenue: $535.06 million
- Price / Sales: 2.37
- Book Value: $14.79 per share
- Price / Book: 1.84
Profitability:- EBITDA: $49.45 million
- Net Margins: -8.02%
- Return on Equity: -6.37%
- Return on Assets: -3.23%
Debt:- Debt-to-Equity Ratio: 0.48%
- Current Ratio: 2.39%
- Quick Ratio: 1.98%
Misc:- Average Volume: 802,775 shs.
- Beta: 1.68
- Short Ratio: 12.41
Frequently Asked Questions for Acorda Therapeutics (NASDAQ:ACOR)
What is Acorda Therapeutics' stock symbol?
Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."
How were Acorda Therapeutics' earnings last quarter?
Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Thursday, July, 27th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.13 by $0.16. The firm earned $139.40 million during the quarter, compared to the consensus estimate of $139.81 million. Acorda Therapeutics had a negative net margin of 8.02% and a negative return on equity of 6.37%. Acorda Therapeutics's revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 EPS. View Acorda Therapeutics' Earnings History.
When will Acorda Therapeutics make its next earnings announcement?
Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2017?
9 analysts have issued 12-month price targets for Acorda Therapeutics' shares. Their predictions range from $18.00 to $35.00. On average, they anticipate Acorda Therapeutics' share price to reach $23.25 in the next twelve months. View Analyst Ratings for Acorda Therapeutics.
What are analysts saying about Acorda Therapeutics stock?
Here are some recent quotes from research analysts about Acorda Therapeutics stock:
- 1. According to Zacks Investment Research, "Acorda submitted regulatory applications for its late stage Parkinson’s candidate, Inbrija (formerly known as CVT-301) in the U.S. and plans to file for the same in the EU by 2017-end. However, Inbrija recently received a refusal to file letter from the FDA which is concerning as it would delay its commercial launch. Moreover, the company’s key multiple sclerosis drug Ampyra is facing patent challenges in the United States. Hence, Acorda’s dependence on Ampyra for a major part of its revenue is concerning. The company has its share of pipeline setbacks too with discontinuation of a few late stage programe which is also a matter of concern . On the flip side, Ampyra showed improvement in performance sequentially despite patent challenges. The company is also working on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price has outperformed the industry so far this year." (10/18/2017)
- 2. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)
- 3. Cowen and Company analysts commented, "ACOR released Q4 Ampyra revenue and provided 2017 Ampyra guidance, both just." (1/9/2017)
Who are some of Acorda Therapeutics' key competitors?
Some companies that are related to Acorda Therapeutics include Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Array Biopharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Radius Health (RDUS), Acceleron Pharma (XLRN), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), Clinigen Group PLC (CLIN), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK) and Ascendis Pharma A/S (ASND).
Who are Acorda Therapeutics' key executives?
Acorda Therapeutics' management team includes the folowing people:
- Ron Cohen M.D., President,Chief Executive Officer, Director
- Richard P. Batycky Ph.D., Chief Technology Officer and Site Head
- David Lawrence, Chief Business Operations, Principal Accounting Officer
- Andrew R. Blight Ph.D., Chief Scientific Officer
- Jane Wasman J.D., President - International, General Counsel, Corporate Secretary
- Burkhard Blank M.D., Chief Medical Officer
- Andrew Hindman, Chief Business Development Officer
- Lauren M. Sabella, Chief Commercial Officer
- Barry E. Greene, Independent Director
- Peder K. Jensen M.D., Independent Director
Who owns Acorda Therapeutics stock?
Acorda Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
SCOPIA CAPITAL MANAGEMENT LP
(18.20%) and
SCOPIA CAPITAL MANAGEMENT LP
(16.50%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, David Lawrence, Enrique J Carrazana, Ian F Smith, Jane Wasman, Lauren M Sabella, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.
How do I buy Acorda Therapeutics stock?
Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acorda Therapeutics' stock price today?
One share of Acorda Therapeutics stock can currently be purchased for approximately $27.20.
MarketBeat Community Rating for Acorda Therapeutics (NASDAQ ACOR)MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Acorda Therapeutics (NASDAQ:ACOR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.11) |
| Consensus Price Target: | $23.25 (14.52% downside) |
Consensus Price Target History for Acorda Therapeutics (NASDAQ:ACOR)
Analysts' Ratings History for Acorda Therapeutics (NASDAQ:ACOR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/6/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell -> Sell | $20.00 | N/A |  |
| 9/28/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $18.00 | Low | |
| 8/31/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $30.00 -> $26.00 | Low | |
| 8/30/2017 | Janney Montgomery Scott | Reiterated Rating | Hold | $18.00 | Low | |
| 8/29/2017 | Cowen and Company | Reiterated Rating | Buy | $35.00 | Low | |
| 7/10/2017 | Jefferies Group LLC | Initiated Coverage | Hold -> Hold | $22.00 | Medium | |
| 6/6/2017 | J P Morgan Chase & Co | Set Price Target | Hold | $24.00 | Low | |
| 1/8/2017 | Evercore ISI | Set Price Target | Hold | $23.00 | N/A | |
| 11/23/2016 | Leerink Swann | Reiterated Rating | Market Perform | | N/A | |
| 6/1/2016 | Aegis | Boost Price Target | Buy | $40.00 -> $52.00 | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Acorda Therapeutics (NASDAQ:ACOR)Earnings History by Quarter for Acorda Therapeutics (NASDAQ ACOR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $0.69 | | | | | N/A | |
| 7/27/2017 | Q2 2017 | $0.13 | $0.29 | $139.81 million | $139.40 million | View | N/A | |
| 4/27/2017 | Q1 2017 | ($0.16) | ($0.08) | $127.34 million | $119.39 million | View | N/A | |
| 2/14/2017 | Q416 | ($0.18) | $0.05 | $137.90 million | $140.63 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.26) | ($0.04) | $134.01 million | $135.61 million | View | Listen | |
| 7/28/2016 | Q216 | $0.18 | $0.07 | $128.33 million | $127.45 million | View | Listen | |
| 4/28/2016 | Q116 | $0.08 | $0.07 | $115.36 million | $115.90 million | View | Listen | |
| 2/11/2016 | Q415 | $0.22 | $0.28 | $128.24 million | $130.90 million | View | Listen | |
| 10/22/2015 | Q315 | $0.15 | $0.31 | $115.52 million | $148.20 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.01) | $0.31 | $110.84 million | $113.70 million | View | Listen | |
| 4/30/2015 | Q115 | $0.03 | ($0.02) | $100.20 million | $99.85 million | View | N/A | |
| 2/12/2015 | Q414 | $0.15 | $0.33 | $110.80 million | $117.90 million | View | N/A | |
| 10/30/2014 | Q314 | $0.04 | $0.34 | $94.70 million | $106.00 million | View | N/A | |
| 7/31/2014 | Q214 | $0.14 | $0.24 | $91.40 million | $97.13 million | View | N/A | |
| 5/6/2014 | Q114 | $0.04 | $0.08 | $81.30 million | $80.52 million | View | N/A | |
| 2/19/2014 | Q413 | $0.18 | $0.32 | $89.96 million | $92.59 million | View | N/A | |
| 10/31/2013 | Q313 | $0.13 | $0.36 | $90.01 million | $84.92 million | View | Listen | |
| 8/1/2013 | Q2 2013 | $0.09 | $0.25 | $82.57 million | $87.05 million | View | Listen | |
| 5/2/2013 | Q1 2013 | $0.20 | $0.09 | $80.77 million | $71.90 million | View | Listen | |
| 2/13/2013 | Q4 2012 | $0.15 | $0.24 | $78.90 million | $81.47 million | View | Listen | |
| 10/31/2012 | Q312 | $0.10 | $0.38 | $75.20 million | $77.44 million | View | N/A | |
| 7/31/2012 | | $0.27 | $0.27 | | | View | N/A | |
| 5/3/2012 | | $0.27 | $0.36 | | | View | N/A | |
| 2/16/2012 | | $0.24 | $0.40 | | | View | N/A | |
| 11/4/2011 | | $0.82 | $0.47 | | | View | N/A | |
| 8/1/2011 | | $0.10 | $0.01 | | | View | N/A | |
| 5/5/2011 | | $0.17 | ($0.02) | | | View | N/A | |
| 2/17/2011 | | $0.17 | $0.09 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Acorda Therapeutics (NASDAQ:ACOR)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 2 | ($0.03) | $0.26 | $0.12 |
| Q3 2017 | 2 | $0.21 | $0.56 | $0.39 |
| Q4 2017 | 2 | $0.32 | $0.76 | $0.54 |
(Data provided by Zacks Investment Research)
Dividend History for Acorda Therapeutics (NASDAQ:ACOR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Acorda Therapeutics (NASDAQ:ACOR)Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/9/2017 | David Lawrence | Insider | Sell | 250 | $25.40 | $6,350.00 | |
| 8/29/2017 | Scopia Capital Management Lp | Major Shareholder | Buy | 766,201 | $19.23 | $14,734,045.23 | |
| 8/1/2017 | Barry E Greene | Director | Sell | 10,000 | $21.57 | $215,700.00 | |
| 7/31/2017 | Lorin Randall | Director | Sell | 10,000 | $21.66 | $216,600.00 | |
| 6/16/2017 | Ron Cohen | Insider | Buy | 20,000 | $16.95 | $339,000.00 | |
| 5/15/2017 | Andrew A Hindman | Insider | Sell | 7,704 | $15.75 | $121,338.00 | |
| 12/14/2016 | Ron Cohen | Insider | Sell | 40,172 | $20.75 | $833,569.00 | |
| 10/21/2016 | Richard P Batycky | Insider | Sell | 2,063 | $20.30 | $41,878.90 | |
| 10/7/2016 | David Lawrence | Insider | Sell | 250 | $20.82 | $5,205.00 | |
| 10/3/2016 | Jane Wasman | Insider | Sell | 3,750 | $20.78 | $77,925.00 | |
| 9/23/2016 | Jane Wasman | Insider | Sell | 500 | $27.32 | $13,660.00 | |
| 6/22/2016 | David Lawrence | Insider | Sell | 500 | $25.09 | $12,545.00 | |
| 6/8/2016 | Steven M Rauscher | Director | Sell | 1,086 | $27.83 | $30,223.38 | |
| 5/13/2016 | Andrew A Hindman | Insider | Sell | 4,860 | $26.11 | $126,894.60 | |
| 4/19/2016 | Lorin Randall | Director | Sell | 1,488 | $28.68 | $42,675.84 | |
| 1/4/2016 | Ian F. Smith | Director | Sell | 13,231 | $41.85 | $553,717.35 | |
| 12/23/2015 | Jane Wasman | insider | Sell | 10,751 | $43.10 | $463,368.10 | |
| 12/22/2015 | Lauren M. Sabella | insider | Sell | 7,113 | $42.04 | $299,030.52 | |
| 12/21/2015 | Jane Wasman | Insider | Sell | 817 | $42.00 | $34,314.00 | |
| 12/18/2015 | David Lawrence | insider | Sell | 39,026 | $40.63 | $1,585,626.38 | |
| 12/17/2015 | Lauren M. Sabella | insider | Sell | 14,229 | $40.00 | $569,160.00 | |
| 12/1/2015 | Enrique J Carrazana | Insider | Sell | 7,218 | $38.08 | $274,861.44 | |
| 12/1/2015 | Ron Cohen | CEO | Sell | 11,850 | $38.08 | $451,248.00 | |
| 10/19/2015 | Andrew Blight | insider | Sell | 32,500 | $30.87 | $1,003,275.00 | |
| 10/7/2015 | Michael W. Rogers | CFO | Sell | 5,700 | $30.24 | $172,368.00 | |
| 10/5/2015 | Jane Wasman | insider | Sell | 3,750 | $31.75 | $119,062.50 | |
| 10/5/2015 | Ron Cohen | CEO | Sell | 135,000 | $28.03 | $3,784,050.00 | |
| 9/21/2015 | Andrew Blight | insider | Sell | 13,085 | $31.30 | $409,560.50 | |
| 5/15/2015 | Andrew A Hindman | Insider | Sell | 4,779 | $29.82 | $142,509.78 | |
| 1/12/2015 | Enrique J Carrazana | Insider | Sell | 97,993 | $42.21 | $4,136,284.53 | |
| 12/18/2014 | David Lawrence | Insider | Sell | 27,109 | $40.11 | $1,087,341.99 | |
| 12/18/2014 | John P Kelley | Director | Sell | 10,000 | $40.00 | $400,000.00 | |
| 12/1/2014 | David Lawrence | Insider | Sell | 8,898 | $35.60 | $316,768.80 | |
| 12/1/2014 | Lauren M Sabella | VP | Sell | 3,242 | $35.58 | $115,350.36 | |
| 12/1/2014 | Michael W Rogers | CFO | Sell | 230 | $35.58 | $8,183.40 | |
| 12/1/2014 | Ron Cohen | CEO | Sell | 34,394 | $35.59 | $1,224,082.46 | |
| 10/7/2014 | Michael W Rogers | CFO | Sell | 5,700 | $33.10 | $188,670.00 | |
| 10/3/2014 | Jane Wasman | Insider | Sell | 3,750 | $34.13 | $127,987.50 | |
| 9/24/2014 | Jane Wasman | Insider | Sell | 14,923 | $36.00 | $537,228.00 | |
| 8/27/2014 | Jane Wasman | Insider | Sell | 14,923 | $33.00 | $492,459.00 | |
| 12/5/2013 | Lauren Sabella | VP | Sell | 8,797 | $31.81 | $279,832.57 | |
| 12/2/2013 | Enrique Carrazana | Insider | Sell | 1,640 | $33.56 | $55,038.40 | |
| 10/15/2013 | Enrique J Carrazana | Insider | Sell | 3,333 | $32.38 | $107,922.54 | |
| 10/3/2013 | Jane Wasman | Insider | Sell | 3,750 | $35.74 | $134,025.00 | |
| 8/20/2013 | Ron Cohen | CEO | Sell | 149,000 | $34.10 | $5,080,900.00 | |
| 8/2/2013 | John Kelley | Director | Sell | 15,000 | $38.00 | $570,000.00 | |
| 7/19/2013 | Andrew Blight | Insider | Sell | 19,296 | $37.82 | $729,774.72 | |
| 6/10/2013 | Ron Cohen | CEO | Sell | 11,000 | $34.15 | $375,650.00 | |
| 5/8/2013 | Sandra Phd Panem | Director | Sell | 10,000 | $33.80 | $338,000.00 | |
| 12/4/2012 | Lauren M Sabella | VP | Sell | 4,364 | $24.58 | $107,267.12 | |
| 12/3/2012 | Andrew Blight | Insider | Sell | 7,200 | $24.20 | $174,240.00 | |
| 12/3/2012 | David Lawrence | CFO | Sell | 9,313 | $24.21 | $225,467.73 | |
| 12/3/2012 | Ron Cohen | CEO | Sell | 16,407 | $24.22 | $397,377.54 | |
| 11/13/2012 | Sandra Phd Panem | Director | Sell | 22,569 | $24.12 | $544,364.28 | |
(Data available from 1/1/2013 forward)
Headline Trends for Acorda Therapeutics (NASDAQ:ACOR)
Latest Headlines for Acorda Therapeutics (NASDAQ:ACOR)
| Source: |
|
| Date | Headline |
|---|
 | Acorda Therapeutics (ACOR) and Vertex Pharmaceuticals (VRTX) Head to Head Analysis
www.americanbankingnews.com - October 20 at 10:30 PM |
 | Pricing Pressure, Competition Remain Headwinds for Pharma Stocks
finance.yahoo.com - October 18 at 8:52 PM |
| Acorda Therapeutics, Inc. (ACOR) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - October 18 at 1:50 PM |
| Acorda Therapeutics, Inc. (ACOR) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 2:58 AM |
| Acorda Therapeutics, Inc. (ACOR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 12 at 6:56 PM |
 | Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board - GlobeNewswire (press release)
globenewswire.com - October 10 at 8:55 PM |
| Acorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled for October 31, 2017
finance.yahoo.com - October 10 at 3:43 PM |
| Acorda Therapeutics Inc (ACOR): How Does It Impact Your Portfolio?
finance.yahoo.com - October 9 at 9:34 PM |
| $151.15 Million in Sales Expected for Acorda Therapeutics, Inc. (ACOR) This Quarter
www.americanbankingnews.com - October 8 at 5:40 AM |
| Acorda Therapeutics' (ACOR) Sell Rating Reiterated at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - October 7 at 12:58 AM |
 | Goldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Sell - StreetInsider.com
www.streetinsider.com - October 6 at 3:47 PM |
 | Intra-Cellular Therapies Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares Of Common Stock
www.thestreet.com - October 5 at 8:16 PM |
| Intra-Cellular Therapies Announces Commencement Of Enrollment Of A Clinical Trial Evaluating ITI-214 In Patients With Parkinson's Disease
www.thestreet.com - October 4 at 3:12 PM |
| Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating
finance.yahoo.com - October 3 at 3:12 PM |
| Acorda Therapeutics, Inc. (ACOR) Earns Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 30 at 7:56 PM |
 | Acorda: Setback And Opportunity - Seeking Alpha
seekingalpha.com - September 28 at 3:46 PM |
| Form 8-K ACORDA THERAPEUTICS INC For: Sep 27 - StreetInsider.com
www.streetinsider.com - September 28 at 1:42 AM |
| Acorda Therapeutics Inc (ACOR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 17 at 4:46 PM |
 | Acorda to Present at the Cantor Fitzgerald Global Healthcare Conference - Business Wire (press release)
www.businesswire.com - September 13 at 3:44 PM |
| Acorda to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 13 at 3:43 PM |
| Should You Buy Acorda Therapeutics Inc (ACOR) Now?
finance.yahoo.com - September 12 at 8:35 PM |
 | Stocks Under Scanner in the Biotech Space -- Acorda Therapeutics, Advaxis, Xbiotech, and Akebia Therapeutics
www.marketwatch.com - September 12 at 2:04 AM |
| Acorda Therapeutics Earns RS Rating Upgrade
finance.yahoo.com - September 11 at 4:01 PM |
 | Scopia Wants Sale of Acorda Therapeutics - Barron's
www.barrons.com - September 9 at 1:49 AM |
| INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.
finance.yahoo.com - September 8 at 3:47 PM |
| Stocks Showing Rising Market Leadership: Acorda Therapeutics Earns 83 RS Rating
finance.yahoo.com - September 7 at 3:21 PM |
| ETFs with exposure to Acorda Therapeutics, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:21 PM |
| Featured Company News – Acorda Therapeutics Adopts Poison Pill
finance.yahoo.com - September 5 at 3:41 PM |
| Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 3:41 PM |
| Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : September 2, 2017
finance.yahoo.com - September 2 at 2:01 AM |
| Acorda Therapeutics, Inc. - StreetInsider.com
www.streetinsider.com - September 1 at 3:56 PM |
| Acorda Adopts Shareholder Rights Plan
finance.yahoo.com - September 1 at 3:55 PM |
 | BRIEF-Scopia Capital Management ups its stake in Acorda Therapeutics to 18.2 pct from previous stake of 16.5 pct
www.reuters.com - August 31 at 8:22 PM |
| Acorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc.; Encourages Investors to Contact the Firm
finance.yahoo.com - August 31 at 8:22 PM |
| Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : August 30, 2017
finance.yahoo.com - August 31 at 8:22 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics Inc. (ACOR)
finance.yahoo.com - August 31 at 8:22 PM |
| Janney Montgomery Scott Reiterates "Hold" Rating for Acorda Therapeutics, Inc. (ACOR)
www.americanbankingnews.com - August 31 at 7:34 PM |
| Scopia Capital Management Lp Buys 766,201 Shares of Acorda Therapeutics, Inc. (ACOR) Stock
www.americanbankingnews.com - August 31 at 7:20 PM |
| Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update
finance.yahoo.com - August 31 at 3:21 PM |
| Stifel Nicolaus Reaffirms Buy Rating for Acorda Therapeutics, Inc. (ACOR)
www.americanbankingnews.com - August 31 at 2:32 PM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc. - Business Wire (press release)
www.businesswire.com - August 30 at 8:27 PM |
| ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - August 30 at 8:27 PM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc.
finance.yahoo.com - August 30 at 8:27 PM |
 | Acorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc ... - PR Newswire (press release)
www.prnewswire.com - August 30 at 3:26 PM |
| AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug
finance.yahoo.com - August 30 at 3:26 PM |
| Acorda Therapeutics, Inc. (ACOR) Receives "Hold" Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 30 at 2:28 PM |
| Acorda Therapeutics' (ACOR) Buy Rating Reiterated at Cowen and Company
www.americanbankingnews.com - August 30 at 2:28 PM |
| Acorda Therapeutics, Inc. Investor Alert: Legal Investigation for Potential Securities Law Violations - Business Wire (press release)
www.businesswire.com - August 29 at 8:49 PM |
| Acorda Therapeutics, Inc. Investor Alert: Legal Investigation for Potential Securities Law Violations
finance.yahoo.com - August 29 at 8:49 PM |
| ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ... - Business Wire (press release)
www.businesswire.com - August 29 at 3:47 PM |
Acorda Therapeutics (ACOR) Chart for Friday, October, 20, 2017
